
Index

A

ADCC, *see* Antibody-dependent cytotoxicity

ADCML, *see* Antibody-dependent complement mediated lysis

Adenovirus expression, bispecific diabodies,

applications, 421

cloning into pShuttle, 426

density gradient centrifugation of virus, 429

electrocompetent bacteria

preparation, 424, 427, 431

enzyme-linked immunosorbent assay, 425, 431

infection of mice, 431

materials, 423–425

overview, 421–423

positive clone screening, 427, 428, 432

recombinant adenovirus generation, 424–427, 431

recombination into pAdEasy-1, 426, 427, 431

single-chain diabody construction, 423–426

titering of virus, 429–432

transfection, 428, 432

virus production on large scale, 428, 429, 432

Affinity,

binding site barrier effect, 38

definition, 37

light-chain shuffling for enhancement, 37

valency of antigen binding effects, 38

Affinity maturation, *see also* Focused complementary-determining region phage libraries, rate constant considerations, 216, 217

Vitaxin, 215, 216

Affinity purification, *see* Cellulose-binding domain fusion proteins; gp96; Nickel affinity chromatography

Antibody-dependent complement mediated lysis (ADCML), complement cascade, 384 immunoglobulin G,

engineering,

cloning into expression vector, 385, 386, 398

expression in J558L cells, 385–387

materials, 384, 385

NIP IgG3, 387, 388

polymerase chain reaction mutagenesis, 384, 385, 388, 389

initiation requirements, 383, 384

Antibody-dependent cytotoxicity (ADCC), recombinant antibody mediation, 35, 383

Antigen-presenting cell (APC), *see* Immunotoxin

Antigens, selection for cancer therapy, 34

APC, *see* Antigen-presenting cell

B

Ber-H2 chimerization, *see* ChimBer-H2

BIAcore, *see* Surface plasmon resonance

Bioreactor,

antibody fragment production,

bioreactor preparation and
cultivation, 440, 441

density of culture, 438

glycerol stock preparation, 439

inoculum culture, 439

materials, 439, 440

periplasmic extraction, 440, 441

rationale, 437, 438

vectors, 437, 438

yield optimization, 438

Escherichia coli expression

advantages, 437

single-chain Fv-CH₃ minibody

production, 357, 360

Bispecific antibody (BsAb),

adenovirus expression of bispecific
diabodies,

applications, 421

cloning into pShuttle, 426

density gradient centrifugation of
virus, 429

electrocompetent bacteria

preparation, 424, 427, 431

enzyme-linked immunosorbent
assay, 425, 431

infection of mice, 431

materials, 423–425

overview, 421–423

positive clone screening, 427,
428, 432

recombinant adenovirus

generation, 424–427, 431

recombination into pAdEasy-1,
426, 427, 431

single-chain diabody

construction, 423–426

titering of virus, 429–432

transfection, 428, 432

virus production on large scale,
428, 429, 432

bivalent bispecific antibodies, 14–16,
305, 306

cancer therapy applications, 305, 323

CD16/CD30 bispecific diabody,
characterization,

cytotoxicity assay, 310,
315, 319

enzyme-linked

immunosorbent assay for
SCID mouse testing, 310,
315, 316, 318

fluorescence-activated cell
sorting analysis of binding,
310, 314

granulocyte isolation, 309,
313, 314, 319

tumor cell transplantation in
SCID mouse, 311, 316,
318, 319

cloning, 311, 312, 318

isolation and purification, 309,
312, 313, 318, 319

large-scale production, 309, 318

materials, 306, 309–311

primers, 306, 307, 318

rationale for construction, 305

construction approaches, 323–325
definition, 14

pharmacokinetics, 323, 325

tandem diabody, *see* Tandab

tetravalent bispecific antibodies, 16

BsAb, *see* Bispecific antibody

C

Carcinoembryonic antigen (CEA),

antibody production in plants, 458, 460

antibody targeting in cancer, 354

colorectal cancer expression, 353, 458

- tissue distribution, 353, 354
- CD16,
 - bispecific diabody, *see* Bispecific antibody,
 - immune cell expression, 305
- CD20 antibody, *see* Rituximab
- CD30,
 - antibody, *see* ChimBer-H2
 - bispecific diabody, *see* Bispecific antibody
 - expression in lymphoma, 63, 305
- CD40, recombinant antibody binding and effector functions, 36
- CDR, *see* Complementary-determining region
- CEA, *see* Carcinoembryonic antigen
- Cellulose-binding domain fusion proteins,
 - refolding application, 444, 445
 - single-chain antibody isolation, bacteria growth, 448
 - cellulose-assisted refolding, 450
 - inclusion bodies,
 - nickel affinity chromatography, 450
 - preparation, 447, 449, 450, 452, 453
 - solubilization, 450
 - materials, 446, 447, 452
 - overview, 445
 - proteolysis while bound on cellulose matrix, 451, 452
 - purification of cellulose-bound protein, 450, 451, 453
 - vector construction, 447, 448, 452, 453
- stability, 445
- ChimBer-H2,
 - CD30 binding by Ber-H2, 63
 - production,
 - complementary DNA tailing, 71
 - enzyme-linked immunosorbent assay, 75, 77, 78
 - expression, 69, 70, 74–78
 - genomic DNA preparation from hybridoma cells, 66, 70, 76
 - materials, 65, 66, 68–70, 76
 - polymerase chain reaction,
 - anchor-PCR, 71, 72
 - complementary DNA synthesis, 66, 68, 70, 71, 76
 - primers, 65, 66
 - variable gene segments, 68, 69, 72, 73, 77
 - principles, 63, 65
 - reverse transcription for complementary DNA synthesis, 66, 68, 70, 71, 76
 - RNA preparation from hybridoma cells, 66, 70, 76
 - transfection of myeloma cells, 69, 74, 77
 - variable gene segment cloning into eukaryotic expression vectors, 68, 69, 73, 74, 77
 - vectors, 66, 67
- Chimeric antibodies, *see also* Humanized antibody
 - Ber-H2 chimerization, *see* ChimBer-H2
 - cancer therapy rationale, 27, 28
 - rodent antibodies with human constant regions, 5
- Chimeric immune receptors, *see* Single-chain Fv chimeric immune receptors
- Colorectal cancer, carcinoembryonic antigen expression, 353, 458
- Complementary-determining region (CDR),
 - focused combinatorial libraries for affinity maturation with kinetic tailoring, *see* Focused complementary-determining region phage libraries
 - grafting for antibody humanization, binding analysis, 88

- enzyme-linked immunosorbent assay, 86, 87, 90, 98, 99
 - expression in mammalian cells,
 - electroporation, 90, 98
 - important sequences, 82, 85
 - vectors, 86
 - materials, 88–90
 - murine variable region,
 - analysis, 82, 83, 85
 - complementary DNA preparation from hybridomas, 88, 91
 - gene cloning, 82, 88, 91, 92, 99
 - overview, 5, 6, 81, 82, 197, 198
 - polymerase chain reaction,
 - assembly for human variable region reshaping, 97, 99
 - heavy-chain variable region primers, 84
 - kappa light-chain variable region primers, 84
 - materials, 88
 - murine variable region cloning, screening, and modification, 88, 89, 91–93, 99
 - primer design for human variable region reshaping, 96, 97, 99
 - reshaped human variable region genes,
 - amino acid sequence analysis, 93–95, 99
 - construction, 86, 96, 97, 99
 - design, 85, 86, 89, 95, 96
 - template selection, 93–95, 99
 - semisynthetic library generation, *see* Semisynthetic antibody phage library
 - variability, 123
 - Corn, recombinant antibody production, 458
- D**
- Disulfide bond,
 - shuffling in recombinant proteins, 443
 - stabilization of domains in Fv fragments, 9, 11, 238, 239, 255, 256
 - DNA immunization, antibody generation,
 - booster immunization, 61
 - immunization, 59–61
 - materials, 58, 59, 61
 - principles, 58–60
 - rationale, 57, 58
 - screening of serum, 59, 61
 - Drug-carrying antibodies, stability requirements, 237, 238
- E**
- ELISA, *see* Enzyme-linked immunosorbent assay
 - Enzyme-linked immunosorbent assay (ELISA),
 - adenovirus-expressed bispecific diabodies, 425, 431
 - CD16/CD30 bispecific diabody, SCID mouse testing, 310, 315, 316, 318
 - ChimBer-H2, 75, 77, 78
 - complementary-determining region-grafted humanized antibody, 86, 87, 90, 98, 99
 - DNA immunization, antibody generation screening of serum, 61
 - gp96-binding single-chain Fv fragments, 398, 399, 408
 - interferon- γ expression in T cells, 377, 378
 - phage-ELISA, 111, 116, 119, 154, 157
 - single-chain Fv-CH₃ minibody, 356, 359, 360

single point ELISA, 204, 205, 210, 226, 227

Tandab binding, 330, 332

tobacco-expressed antibodies, 462

F

Fab antibody phage library,

affinity maturation with kinetic tailoring, *see* Focused complementary-determining region phage libraries

folate receptor targeting in ovarian cancer,

characterization of Fabs, 155

electroporation of ligation reactions, 151

fluorescence-activated cell sorting screening, 154

guided selection principles, 147

half-human library preparation, 152, 153

ligation, 151, 156

light chain selection,

cloning, 155

overview, 154, 155, 157

phage rescue, 155

transformation, 155

materials for screening, 147–149

phage production, 151, 152

phage-ELISA screening, 154, 157

polymerase chain reaction,

human V gene

amplification, 149, 150

murine V_LC_L gene

amplification, 152

primers, 150

restriction site introduction for cloning, 150

reverse transcription-PCR, 149

RNA extraction from peripheral

blood lymphocytes, 149, 156

selection on carcinoma cell

monolayers,

cell preparation, 153, 156

infection with bound phage, 153, 154, 157

panning, 153, 157

phage production, 154

V_LC_L gene cloning, 152, 156

T cell receptor-like specific human library generation,

competent cell preparation, 166, 169, 174

complementary DNA preparation, 167

electroporation, 166, 169, 170

gene cloning, 168, 169

HLA-A2,

overexpression, 167, 172, 173

purification, 173, 174

refolding from inclusion bodies, 167, 173

materials, 163–167

overview, 161, 162, 269, 270

panning, 166, 167, 171, 172, 175

phage production and titration, 166, 170, 171, 174

polymerase chain reaction,

amplification reactions, 168, 174

primers, 163–166

RNA extraction, 167

Fab fragments,

bioreactor production, *see* Bioreactor cellulose-binding domain fusion

proteins, *see* Cellulose-binding domain fusion proteins

FACS, *see* Fluorescence-activated cell sorting

FcεRIγ, *see* Single-chain Fv chimeric immune receptors

Fluorescence-activated cell sorting (FACS),

- CD16/CD30 bispecific diabody
 - analysis of binding, 310, 314
- Fab antibody phage library
 - screening, 154
- immunotoxin characterization against
 - antigen-presenting cells, 279
- single-chain Fv chimeric immune receptor expression, 375, 376, 380
- Focused complementary-determining region phage libraries,
 - affinity maturation with kinetic tailoring, overview, 214–217, 219
 - combinatorial mutant construction, screening, and characterization, 228
- Fab,
 - isolation from periplasmic space, 226–228
 - quantification, 228
- materials for construction, 219, 220
- modified codon-based mutagenesis, 223, 224, 228, 229
- screening,
 - k_{off} -driven screening,
 - capture lift assay, 225, 226
 - single-point ELISA, 226, 227
 - k_{on} -driven screening, 227, 229, 230
 - overview, 225
- single-mutation library construction and characterization, 224, 225
- variable region gene cloning into phage vector,
 - hybridization mutagenesis, 222, 228
 - overview, 220
 - polymerase chain reaction, 221
 - single-stranded DNA isolation, 221
 - uridynylated template preparation, 221, 222
- Folate receptor Fab fragment library,
 - see* Ovarian cancer
- Fv fragments,
 - binding ability of domains, 133, 134
 - bioreactor production, *see* Bioreactor
 - bispecific antibody production, *see* Bispecific antibody; Tandab
 - bivalent and multivalent construct production, 12, 14
 - cancer therapy overview, 28, 29
 - cellulose-binding domain fusion proteins, *see* Cellulose-binding domain fusion proteins
 - chimeric immune receptors, *see* Single-chain Fv chimeric immune receptors
 - disulfide stabilization of domains, 9, 11, 238, 239, 255, 256
 - hot spots for antigen binding, 180
 - immunotoxin, *see* Immunotoxin
 - minibody, *see* Single-chain Fv-CH₃ minibody
 - pharmacokinetics, 37, 352, 353
 - ribonuclease fusion proteins, *see* Ribonuclease-Fv fusion proteins
 - single antibody-like domains, 11, 12
 - single-chain fragment,
 - multimeric antibody construction, *see* Multimeric antibodies
 - phage expression libraries, *see* Semisynthetic antibody phage library; Single-chain Fv fragment phage expression library
 - production in bacteria, 10, 11
 - stability engineering by mutagenesis, instability factors, 239
 - mutagenesis of problematic residues,
 - annealing reaction, 250
 - ligase-PCR, 251
 - oligonucleotide design and phosphorylation, 249, 250
 - primer extension, 250, 251
 - template preparation, 247–249, 252, 253

- mutant characterization, 251, 252
- problematic residue identification,
 - materials, 240, 241
 - overview, 239, 240
 - tables and uses, 242–247, 252
- rationale, 237, 238
- structure, 238

G

gp96,

- antigen presentation, 393
- function, 393
- single-chain Fv fragment
- affinity purification,
- affinity chromatography,
 - chromatography conditions, 402, 412, 413, 415
 - column preparation, 401, 412
- characterization,
 - dot-blot analysis, 399, 408, 409, 413, 415
 - enzyme-linked immunosorbent assay, 398, 399, 408
 - gel electrophoresis, 397, 398, 407, 415
 - Western blot, 397, 398, 407, 408, 415
- expression,
 - fragment cloning into pHOG21, 395, 396, 404, 405, 413, 414
 - induction, 400, 410, 411
 - materials, 396, 397, 400, 401
 - small-scale expression, 396, 397, 405, 406, 414
- immunoprecipitation,
 - bead preparation, 409, 410, 415
 - cell lysate preparation, 409, 415
 - materials, 399, 400
 - precipitation and washing, 410

- nickel affinity chromatography of fragments, 397, 400, 406, 411, 412, 414, 415
- phage expression library screening,
 - advantages, 393, 394
 - DNA fingerprinting and sequencing of clones, 403, 404, 413
 - materials, 394, 395, 413
 - overview, 402, 403
 - phagemid particle isolation, 403

- Granulocyte, isolation for CD16/CD30 bispecific diabody characterization, 309, 313, 314, 319

GRP94, *see* gp96**H**Herceptin, *see* TrastuzumabHLA-A2, *see* Fab antibody phage library

- Humanized antibody, *see also* Chimeric antibodies,
 - affinity optimization simultaneously with humanization, capture lift assay, 203, 210
 - chimeric Fab construction,
 - cloning variable regions into phage expression vector, 202
 - overview, 201
 - single-stranded DNA preparation, 201, 202, 210
 - combinatorial framework-HCDR3 phage library,
 - construction, 206, 208, 210
 - replicate filter assay, 209
 - screening and clone characterization, 209
 - sequencing, 209
 - materials, 199–201
 - principles, 198, 199

- single point ELISA, 204, 205, 210
- cancer therapy overview, 28
- complementary-determining region
 - grafting,
 - binding analysis, 88
 - enzyme-linked immunosorbent assay, 86, 87, 90, 98, 99
 - expression in mammalian cells,
 - electroporation, 90, 98
 - important sequences, 82, 85
 - vectors, 86
 - materials, 88–90
 - murine variable region,
 - analysis, 82, 83, 85
 - complementary DNA preparation from hybridomas, 88, 91
 - gene cloning, 82, 88, 91, 92, 99
 - overview, 5, 6, 81, 82, 197, 198
 - polymerase chain reaction,
 - assembly for human variable region reshaping, 97, 99
 - heavy-chain variable region primers, 84
 - kappa light-chain variable region primers, 84
 - materials, 88
 - murine variable region cloning, screening, and modification, 88, 89, 91–93, 99
 - primer design for human variable region reshaping, 96, 97, 99
 - reshaped human variable region genes,
 - amino acid sequence analysis, 93–95, 99
 - construction, 86, 96, 97, 99
 - design, 85, 86, 89, 95, 96
 - template selection, 93–95, 99
 - engineering principles, 3, 197
 - human anti-mouse antibody immune response, 33, 34, 81
 - pharmacokinetics, 37
 - resurfacing, 7, 28

I

 - IgG, *see* Immunoglobulin G
 - IMAC, *see* Immobilized metal affinity chromatography
 - Immobilized metal affinity chromatography (IMAC), *see* Nickel affinity chromatography
 - Immunofluorescence, DNA immunization, antibody generation screening of serum, 61
 - Immunoglobulin E receptor, *see* Single-chain Fv chimeric immune receptors
 - Immunoglobulin G (IgG),
 - antibody-dependent complement mediated lysis (ADCML), initiation requirements, 383, 384
 - engineering,
 - cloning into expression vector, 385, 386, 398
 - expression in J558L cells, 385–387
 - materials, 384, 385
 - NIP IgG3, 387, 388
 - polymerase chain reaction mutagenesis, 384, 385, 388, 389
 - domain organization, 3, 4
 - engineering advantages, 7
 - pharmacokinetics, 37
 - subclasses, 7, 8
 - Immunoprecipitation, *see* gp96
 - Immunotoxin,
 - antigen-presenting cell targeting with Fv-MHC-tumor peptide complexes, characterization,

- binding assays, 278–281
 - cytotoxicity assays, 277, 278, 280, 281
 - fluorescence-activated cell sorting analysis of peptide presentation, 279
 - quantitative analysis, 277, 280
 - inclusion body,
 - dialysis of protein, 275
 - isolation, 272, 274, 280
 - solubilization and refolding, 272–275, 280
 - materials, 270, 272, 273
 - overview, 269, 270
 - plasmids, 270, 273
 - purification,
 - ion-exchange chromatography, 276, 280
 - MHC-peptide complexes, 276, 277
 - size exclusion chromatography, 276
 - transformation, 272
 - transformation, 273, 274, 279, 280
 - Pseudomonas* exotoxin Fv
 - immunotoxin, characterization,
 - binding assays, 263, 264
 - cytotoxicity assays, 263
 - quantitative analysis, 262, 265
 - construction,
 - design and engineering overview, 255, 256, 258
 - disulfide bond stabilization, 256, 257, 259, 260
 - inclusion body protein isolation and refolding, 260–262, 264
 - materials, 256, 257
 - mechanism of action, 256
 - plasmid preparation, 257, 259, 260
 - transformation, 260, 264
 - purification,
 - ion-exchange chromatography, 262
 - size exclusion chromatography, 262
 - Inclusion body,
 - cellulose-binding domain fusion proteins,
 - nickel affinity chromatography, 450
 - preparation, 447, 449, 450, 452, 453
 - solubilization, 450
 - Fv-MHC-tumor peptide complex,
 - dialysis of protein, 275
 - isolation, 272, 274, 280
 - solubilization and refolding, 272–275, 280
 - HLA-A2 refolding, 167, 173
 - Pseudomonas* exotoxin Fv
 - immunotoxin isolation and refolding, 260–262, 264
 - refolding optimization, 444
 - ribonuclease-Fv fusion protein,
 - folding from crude inclusion bodies, 294–296
 - folding from purified inclusion bodies, 292, 293
 - isolation, 292
 - overview, 291, 292
- ## M
- MAb 4D5
 - HER2 binding, 6, 32
 - humanization, *see* Trastuzumab
 - MAb anti-B4, humanization, 7
 - Minibody, *see* Single-chain Fv-CH₃ minibody
 - Multimeric antibodies,
 - binding assays, 346
 - expression from single-chain Fv fragments,

affinity chromatography, 344, 345, 348
 cell fractionation and isolation, 343, 344, 347, 348
 induction time optimization, 342, 345, 347
 shake flask expression and fractionation, 342, 347
 rationale for construction, 335
 single-chain Fv fragments, applications, 335, 336
 construction,
 cloning into pPOW3, 339–342
 C-terminal peptide tags, 340, 347
 media, 337, 338, 346
 overview, 335, 336
 polymerase chain reaction, 341
 primers, 336, 337, 339, 340, 346, 347
 transformation and colony selection, 341, 342, 347
 vector for expression, 336, 346
 design, 335
 stability optimization, 345, 348
 storage, 345
 V domain linkage for triabody synthesis, 341

N

NHL, *see* Non-Hodgkin's lymphoma
 Nickel affinity chromatography,
 cellulose-binding domain fusion proteins, 450
 gp96-binding single-chain Fv fragments, 397, 400, 406, 411, 412, 414, 415
 tobacco-expressed antibodies, 463
 Non-Hodgkin's lymphoma (NHL),
 Rituximab treatment efficacy, 5, 30–32

O

Ovarian cancer,
 antigen targets, 145, 146
 chemotherapy, 145
 Fab antibody phage library against folate receptor,
 characterization of Fabs, 155
 electroporation of ligation reactions, 151
 fluorescence-activated cell sorting screening, 154
 guided selection principles, 147
 half-human library preparation, 152, 153
 ligation, 151, 156
 light chain selection,
 cloning, 155
 overview, 154, 155, 157
 phage rescue, 155
 transformation, 155
 materials for screening, 147–149
 phage-ELISA screening, 154, 157
 phage production, 151, 152
 polymerase chain reaction,
 human V gene amplification, 149, 150
 murine V_LC_L gene amplification, 152
 primers, 150
 restriction site introduction for cloning, 150
 reverse transcription-PCR, 149
 RNA extraction from peripheral blood lymphocytes, 149, 156
 selection on carcinoma cell monolayers,
 cell preparation, 153, 156
 infection with bound phage, 153, 154, 157
 panning, 153, 157
 phage production, 154
 V_LC_L gene cloning, 152, 156

P

PCR, *see* Polymerase chain reaction

PET, *see* Positron emission tomography

Phage display antibody libraries,
affinity,

antibodies, 213, 214

engineering, 37

affinity optimization simultaneously
with humanization,

capture lift assay, 203, 210

chimeric Fab construction,

cloning variable regions into

phage expression vector, 202

overview, 201

single-stranded DNA

preparation, 201, 202, 210

combinatorial framework-HCDR3

phage library,

construction, 206, 208, 210

replicate filter assay, 209

screening and clone

characterization, 209

sequencing, 209

materials, 199–201

principles, 198, 199

single point ELISA, 204, 205, 210

applications, 29, 30

Fab libraries, *see* Fab antibody phage
library

focused combinatorial libraries for

affinity maturation with kinetic
tailoring, *see* Focused

complementary-determining
region phage libraries

guided selection, 145, 147

historical perspective, 29

human antibody production, 8, 9

semisynthetic libraries, *see*

Semisynthetic antibody phage
library

single-chain Fv fragment, *see*

Semisynthetic antibody phage

library; Single-chain Fv

fragment phage expression

library

Pharmacokinetics,

antibody fragments, 37, 39, 352, 353

bispecific antibodies, 323, 325, 353

definition, 36

recombinant antibodies, 37

Polymerase chain reaction (PCR),

antibody-dependent complement

mediated lysis, mutagenesis

for engineering, 384, 385,

388, 389

ChimBer-H2 generation,

anchor-PCR, 71, 72

complementary DNA synthesis,

66, 68, 70, 71, 76

primers, 65, 66

variable gene segments, 68, 69,

72, 73, 77

complementary-determining region-
grafted humanized antibody

generation,

assembly for human variable

region reshaping, 97, 99

heavy-chain variable region

primers, 84

kappa light-chain variable region

primers, 84

materials, 88

murine variable region cloning,

screening, and modification,
88, 89, 91–93, 99

primer design for human variable

region reshaping, 96, 97, 99

ribonuclease-Fv fusion protein gene

construction, 284–286, 289–291

semisynthetic antibody phage library

construction, 127–130

single-chain diabody construction,

423–426

single-chain Fv chimeric immune

receptor construction,

- amplification reactions, 369, 378
 - primers, 368–371, 379
 - reverse transcription-PCR, 378
 - single-chain Fv fragment phage
 - expression library generation, amplification of rearranged variable genes, 112, 116, 117
 - materials, 104, 106, 107
 - primers,
 - V_H primer, 106
 - V_K primer, 107
 - V_γ primers, 108, 109
 - restriction site introduction, 112, 117
 - splicing by overlap extension PCR, 190, 195, 251, 358
 - Tandab construction, 328
 - T cell receptor-like specific human library generation, amplification reactions, 168, 174 primers, 163–166
 - V_H antibody fragment production, library construction, 136
 - V_H randomized CDR3 amplification, 134, 136
 - Positron emission tomography (PET), antibody tracers, 351
 - Pseudomonas* exotoxin immunotoxin, *see* Immunotoxin
- R**
- Retrovirus expression system, *see* Single-chain Fv chimeric immune receptors
 - Ribonuclease-Fv fusion proteins, characterization,
 - binding activity, 287, 296, 297
 - materials, 287, 288
 - ribonuclease activity, 287, 288, 297
 - toxicity assays, 288, 298
 - clinical applications, 283
 - preparation, expression analysis, 286, 291
 - fusion gene construction, 284–286, 289–291
 - materials, 284–287
 - overview, 283, 284
 - purification from inclusion bodies,
 - folding from crude inclusion bodies, 294–296
 - folding from purified inclusion bodies, 292, 293
 - isolation, 292
 - overview, 291, 292
- Rituximab,
 - CD20 binding, 30
 - effector functions, 35, 36
 - lymphoma treatment efficacy, 5, 30–32
- S**
- Semisynthetic antibody phage library, applications, 124
 - B cell repertoire library comparison, 123, 124
 - codon use and randomization, 125
 - complementary-determining region, length of randomized region, 124
 - number of amino acid positions randomized, 124
 - selection for randomization, 124
 - single-chain Fv fragment library
 - against 2-phenyloxazol-5-one, cloning into pSEX81phox, 127–130
 - materials, 127, 128
 - overview of construction, 125, 126
 - polymerase chain reaction, 127–130
 - Single-chain Fv-CH₃ minibody, applications, 354, 355
 - carcinoembryonic antigen targeting, 354
 - characterization,
 - BIAcore analysis of binding, 361
 - gel electrophoresis, 361
 - quantification, 361

- size exclusion chromatography, 361
- Western blot, 361
- design, 355
- preparation,
 - enzyme-linked immunosorbent assay, 356, 359, 360
 - gene construction, 356
 - hollow fiber bioreactor
 - production, 357, 360
 - materials, 356, 357
 - purification, 357, 360, 362
 - splice overlap extension PCR, 358
 - transfection, 356, 359, 362
 - variable region gene amplification
 - from hybridomas, 358, 361
- Single-chain Fv chimeric immune receptors,
 - construction,
 - expression cassette generation, 373, 380
 - immunoglobulin G Fc domain
 - insertion into expression cassette, 369, 372, 373, 380
 - materials, 366–368, 378
 - polymerase chain reaction,
 - amplification reactions, 369, 378
 - primers, 368–371, 379
 - reverse transcription-PCR, 378
 - rationale, 365
 - retroviral gene transfer, 365, 366, 373
 - vector ligation, 369, 380
- expression,
 - cotransfection of 293 cells with
 - retroviral vector and helper plasmid, 374, 375, 380
 - flow cytometry analysis of
 - expression, 375, 376, 380
 - T cell line stable expression, 373, 374, 380
 - transient expression in 293 cells, 374, 380
- FcεRIγ chimeras, 365, 366
- T cell interferon-γ expression analysis, 377, 378
- T cell receptor chimeras, 365, 366
- Single-chain Fv fragment phage expression library,
 - affinity enhancement with hot spot engineering,
 - binding analysis, 190, 191, 195
 - conventional approaches for
 - affinity improvement, 179
 - hot spots,
 - identification in V region, 183
 - rational selection for mutation, 183, 184
 - library construction and panning, 190, 195
 - materials, 181–183, 191
 - overview, 179–181, 183
 - random mutation,
 - annealing reaction, 188
 - Kunkel's mutagenesis, 189, 190, 195
 - oligonucleotide design, 187, 189, 195
 - oligonucleotide phosphorylation, 187, 188
 - primer extension, 188, 189, 195
 - splicing by overlap extension PCR, 190, 195
 - template preparation for mutagenesis, 185–187, 194, 195
- cloning into pSE81
 - heavy chain cloning into light-chain sublibraries, 113, 114, 117
 - light-chain sublibraries, 113, 117
 - materials, 108–110
- complementary DNA synthesis, 104, 112

- gp96 affinity purification, *see* gp96
 - materials for generation, 104, 106–111, 116
 - overview of construction, 103, 104
 - panning to select for antigen-binding clones, 110, 111, 115, 118
 - phage-enzyme linked
 - immunosorbent assay, 111, 116, 119
 - phage rescue, 110, 111, 114, 115–118
 - polymerase chain reaction,
 - amplification of rearranged variable genes, 112, 116, 117
 - materials, 104, 106, 107
 - primers,
 - V_H primer, 106
 - V_K primer, 107
 - V_γ primers, 108, 109
 - restriction site introduction, 112, 117
 - rationale, 103
 - reinfection of bacteria with enriched phage clones, 110, 111, 115, 116, 118
 - RNA extraction, 104, 112
 - semisynthetic library, *see* Semisynthetic antibody phage library
 - V_H antibody fragments,
 - applications, 134
 - cloning,
 - expression vector, 138, 139
 - phagemid vector, 134, 135
 - materials for production, 134–136
 - panning of library on antigen, 135, 137, 138
 - phage clone characterization, 135, 138
 - phage preparation for selection,
 - precipitation, 137
 - rescue, 136, 137
 - polymerase chain reaction,
 - library construction, 136
 - VH randomized CDR3 amplification, 134, 136
 - protein production, 135, 136, 139–142
 - purification,
 - ion-exchange chromatography, 140
 - size-exclusion chromatography, 140, 141
 - Soybean, recombinant antibody production, 458
 - SPR, *see* Surface plasmon resonance
 - Surface plasmon resonance (SPR),
 - single-chain Fv-CH3 minibody binding, 361
- T**
- Tandab,
 - applications, 325
 - enzyme-linked immunosorbent assay of binding, 330, 332
 - preparation,
 - bacteria culture, 329, 331
 - materials, 325–328, 331
 - overview, 325
 - plasmid generation,
 - cloning into expression vector, 328, 329, 331
 - polymerase chain reaction, 328
 - purification, 329–332
 - structure, 325
 - T-cell receptor, *see* Single-chain Fv chimeric immune receptors
 - Tobacco expression system,
 - advantages of antibody expression, 455, 456
 - applications, 456
 - carcinoembryonic antigen antibody production,
 - Agrobacterium* preparation, 461, 463

- enzyme-linked immunosorbent assay, 462
 - extraction from leaves, 462
 - materials, 460, 461, 463
 - overview, 458, 460
 - purification,
 - nickel affinity chromatography, 463
 - protein A column chromatography, 462
 - yields, 463
 - transformation and regeneration of plants, 461, 462
 - types of antibodies, 458
 - Western blot, 462
 - CaroRx production, 457, 458
 - expression strategies,
 - agroinfiltration, 456, 457
 - particle bombardment, 456, 457
 - viral vectors, 456, 457
 - Transgenic mouse, human antibody production, 8, 30
 - Transgenic tobacco, *see* Tobacco expression system
 - Trastuzumab,
 - breast cancer metastasis trials, 32, 33
 - effector functions, 36
 - HER2 binding, 6, 32
 - humanization, 6, 32
- V**
- Variable regions, cloning, 4
 - Vitaxin, affinity maturation, 215, 216
- W**
- Western blot,
 - DNA immunization, antibody generation screening of serum, 61
 - gp96-binding single-chain Fv fragments, 397, 398, 407, 408, 415
 - single-chain Fv-CH₃ minibody, 361
 - tobacco-expressed antibodies, 462